Biotech Cel-Sci Stock Joins Rank Of Stocks With RS Ratings Over 90

On Wednesday, Cel-Sci (CVM) reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 92, up from 89 the day before.

As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. This exclusive rating from Investor’s Business Daily measures price action with a 1 (worst) to 99 (best) score. The score shows how a stock’s price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.

Decades of market research shows that the market’s biggest winners typically have an RS Rating north of 80 in the early stages of their moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Is Cel-Sci Stock A Buy?

Since breaking out on Jan. 27 to a 52-week high of 40.91, Cel-Sci stock has been building its right side of  a consolidation with a 41.10 entry, meaning it’s now out of a proper buy zone. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.

The company reported negative growth for both the top and bottom lines last quarter. The company is expected to report its next quarterly numbers on or around May 8.

Cel-Sci stock earns the No. 71 rank among its peers in the Medical-Biomed/Biotech industry group. Horizon Therapeutics (HZNP), Alexion Pharmaceuticals (ALXN) and Halozyme Therapeutics (HALO) are among the top 5 highly rated stocks within the group. For more industry news, check out “Biotech And Pharma Industry And Stock News.”


MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Most Related Links :
usnewsmail Governmental News Finance News

Source link

Back to top button